Nexium cools in 2Q; scale up in respiratory remains critical ffInvagen could act as a transformational catalyst, albeit in the long term, with US contributing 20% to overall sales. However, we assess that most of the products are me-too oral solids lacking differentiation. Besides, it has not received any...